External factors: | Doxorubicin |
Aging type: | Accelerate |
Aging characteristic: |
Category: | Chemical compounds |
Phenotype: | Aging |
Experiment: | SA-β-gal activity assay |
Description: | Thus in order to induce senescence we treated BJ cells with 50 and 100 ng/ml of doxorubicin for 5 days as suggested in literature [38]. Induction of senescence was evident with increased SA-β-gal activity, increased levels of p53 and p21CIP1 and γ-H2A.X foci formation. |
Target gene: | SIRT1//SIRT3 |
R-EF-Target gene: | Downregulation//Downregulation |
Official symbol(s): | SIRT1//SIRT3 |
Target gene experiment: | Western blot |
Target gene description: | Remarkably WB analysis showed that expressions of SIRT1/2 were also slightly reduced during doxorubicin induced senescence. |
Regulatory pathway: | p53-p21 |
R-EF-Pathway: | Activation |
Official symbol(s): | TP53-CDKN1A |
Pathway experiment: | SA-β-gal activity assay//Western blot |
Pathway description: | Additionally, when we tested p16 INK4A levels we found rather minor increase in p16INK4A levels suggesting doxorubicin induced senescence is mediated mainly by activation of p53-p21 pathway . |
Annotation: